Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azd8630
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Inhalation
01
Overview
AZD8630 (also known as AMG 104) is an investigational biologic drug being developed for the treatment of uncontrolled asthma in adults. It is a human IgG1 lambda Fab fragment that targets and inhibits thymic stromal lymphopoietin (TSLP), a cytokine involved in airway inflammation associated with asthma. By blocking TSLP, AZD8630 aims to reduce airway inflammation and decrease the risk of asthma exacerbations. The drug is administered via inhalation using a dry powder inhaler and is currently in Phase 2 clinical trials for patients with moderate-to-severe or uncontrolled asthma who remain symptomatic despite standard therapy. The development of AZD8630 is led by AstraZeneca in collaboration with Amgen[4][5][7][8].
- Other names
- human igg1 lambda fab fragment against thymic stromal lymphopoietin
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on azd8630.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azd8630.